Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...

Podrobná bibliografie
Hlavní autoři:	Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E
Médium:	Journal article
Vydáno:	BioMed Central 2018

Podobné jednotky

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
Autor: Philip Helliwell, a další
Vydáno: (2018-10-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
Autor: Helliwell, P, a další
Vydáno: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
Autor: Nash, P, a další
Vydáno: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
Autor: Nash, P, a další
Vydáno: (2018)

Janus kinase inhibitors in the treatment of psoriatic arthritis
Autor: E. Yu. Loginova, a další
Vydáno: (2022-02-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
Autor: Coates, L, a další
Vydáno: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
Autor: Tucker, L, a další
Vydáno: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
Autor: Miao Chen, a další
Vydáno: (2020-04-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
Autor: Lubrano, E, a další
Vydáno: (2019)

Current concepts and unmet needs in psoriatic arthritis
Autor: Mahmood, F, a další
Vydáno: (2017)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
Autor: Nash, P, a další
Vydáno: (2018)

Remission in psoriatic arthritis—where are we now?
Autor: Coates, L, a další
Vydáno: (2017)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
Autor: P.S. Helliwell
Vydáno: (2011-09-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Autor: Ennio Lubrano, a další
Vydáno: (2019-08-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Autor: Coates, LC, a další
Vydáno: (2024)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
Autor: Coates, L, a další
Vydáno: (2021)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
Autor: Coates, L, a další
Vydáno: (2018)

Best-practice indicators in Psoriatic disease care
Autor: Helliwell, P, a další
Vydáno: (2019)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
Autor: Coates, L, a další
Vydáno: (2016)

What should be the primary target of "treat to target" in psoriatic arthritis?
Autor: Coates, LC, a další
Vydáno: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Autor: Peter Nash, a další
Vydáno: (2018-11-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Autor: Mease, P, a další
Vydáno: (2018)

Psoriatic arthritis
Autor: FitzGerald, O, a další
Vydáno: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
Autor: Laura C. Coates, a další
Vydáno: (2021-03-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
Autor: Jiao Wang, a další
Vydáno: (2025-02-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
Autor: Coates, L, a další
Vydáno: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
Autor: Soriano, ER, a další
Vydáno: (2023)

Psoriatic Arthritis: A Review
Autor: Farrouq Mahmood, a další
Vydáno: (2016-07-01)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
Autor: Helliwell, PS, a další
Vydáno: (2021)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
Autor: E. E. Gubar, a další
Vydáno: (2021-10-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Autor: Laure Gossec, a další
Vydáno: (2024-02-01)

How should we define disease and outcomes in axial psoriatic arthritis?
Autor: Coates, LC
Vydáno: (2021)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
Autor: Vivekanantham, A, a další
Vydáno: (2024)

Measuring outcomes in psoriatic arthritis
Autor: Ogdie, A, a další
Vydáno: (2020)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
Autor: Vishal R. Tandon, a další
Vydáno: (2022-07-01)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
Autor: Braun, J, a další
Vydáno: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Autor: Philip J. Mease, a další
Vydáno: (2023-08-01)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
Autor: Yazji, SM, a další
Vydáno: (2025)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Autor: Nash, P, a další
Vydáno: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
Autor: Coates, LC, a další
Vydáno: (2022)